Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NLNK

NewLink Genetics (NLNK) Stock Price, News & Analysis

NewLink Genetics logo

About NewLink Genetics Stock (NASDAQ:NLNK)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.89
$14.10
52-Week Range
N/A
Volume
N/A
Average Volume
547,540 shs
Market Capitalization
$162.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Receive NLNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewLink Genetics and its competitors with MarketBeat's FREE daily newsletter.

NLNK Stock News Headlines

Reproduction DNA and Genetics
What Wall Street expects from NewLink Genetics's earnings
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Best DNA Test for 2024
Newlink Technology Inc.
Newlink Technology Inc (9600)
See More Headlines

NLNK Stock Analysis - Frequently Asked Questions

NewLink Genetics Corp (NASDAQ:NLNK) issued its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($0.27) EPS for the quarter, meeting analysts' consensus estimates of ($0.27). The biotechnology company had revenue of $0.25 million for the quarter. NewLink Genetics had a negative net margin of 4,592.84% and a negative trailing twelve-month return on equity of 41.50%.

Based on aggregate information from My MarketBeat watchlists, some other companies that NewLink Genetics investors own include Bristol-Myers Squibb (BMY), Inovio Pharmaceuticals (INO), Arbutus Biopharma (ABUS), OPKO Health (OPK), Gilead Sciences (GILD), SunPower (SPWR) and Sarepta Therapeutics (SRPT).

Company Calendar

Last Earnings
11/06/2019
Today
5/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NLNK
Fax
N/A
Employees
55
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$42.99 million
Net Margins
-4,592.84%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$940,000.00
Price / Cash Flow
N/A
Book Value
$2.11 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$162.00 million
Optionable
Not Optionable
Beta
1.17
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:NLNK) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners